Peripheral Artery Disease Market to grow at a CAGR of 8.10% during 2026 to 2035; Driven by Rising Global Diabetes Prevalence and Advancements in Minimally Invasive Endovascular Devices

According to Market Research Future (MRFR), the Peripheral Artery Disease Market reached a valuation of USD 5.90 billion in 2025 and is projected to grow from USD 6.34 billion in 2026 to USD 12.78 billion by 2035. The market includes data points reflecting operations up to 2026. It exhibits a compound annual growth rate (CAGR) of 8.10% during the forecast period from 2026 to 2035. Rising global diabetes prevalence and the expansion of value-based reimbursement models drive this market growth. Technological advancements and the shift toward minimally invasive endovascular devices support this expansion.

The key players operating in the Peripheral Artery Disease Market include Medtronic, Boston Scientific, Abbott Laboratories, Stryker, Philips Healthcare, BD, Cook Medical, Terumo Corporation, Cardinal Health, and AngioDynamics. These companies focus on strategic mergers and acquisitions, pipeline diversification, and developing next-generation thrombectomy and revascularization platforms to strengthen their market positioning.

Market Highlights

The Peripheral Artery Disease Market is experiencing robust growth driven by rising global diabetes and obesity prevalence and the expansion of minimally invasive endovascular devices. North America accounts for around 43.7% of the market, owing to its high diagnostic rate and strong private-payer coverage. The Asia-Pacific region is the fastest-growing market with a CAGR of 9.14%. Europe accounts for the second greatest percentage at over 28.0%. Technological changes include the replacement of older open-surgical techniques with catheter-based endovascular interventions performed in outpatient ambulatory settings.

Segment Analysis

The Peripheral Artery Disease Market has been segmented by treatment type, end user, disease stage, anatomy treated, and region.

By Treatment Type, the Peripheral Artery Disease Market is divided into Devices and Drugs. Devices represent the dominating segment, accounting for 61.2% of the market in 2025 due to the dominance of endovascular platforms and surgical instruments. Pharmaceutical therapies are the fastest-growing treatment category, advancing at a 10.72% CAGR through 2035 as novel antiplatelet and lipid-lowering agents gain regulatory traction.

By End User, the Peripheral Artery Disease Market is divided into Hospitals, Ambulatory Surgical Centers, and Specialty Vascular Clinics. Hospitals represent the dominating segment, controlling 61.5% of the market in 2025, anchored by complex revascularization cases requiring hybrid operating suites. Ambulatory surgical centers are the fastest-growing segment, posting the strongest growth at a 10.28% CAGR, benefiting from same-day discharge protocols and lower procedural costs.

By Disease Stage, the Peripheral Artery Disease Market is divided into Intermittent Claudication and Critical Limb Ischemia. Intermittent claudication represents the dominating segment with a 69.5% share of the market in 2025, given its higher prevalence relative to advanced stages. Critical limb ischemia procedures are the fastest-growing segment, expanding at a 9.24% CAGR driven by improved limb-salvage technologies.

By Anatomy Treated Peripheral Artery Disease Market, it is divided into Lower-Extremity Arteries and Renal-Visceral Arteries. Lower-extremity arterial procedures represent the dominating segment, capturing 83.2% of the market in 2025. Renal-visceral interventions are the fastest-growing segment, projected to grow at a 10.10% CAGR through 2035.

By Region Peripheral Artery Disease Market, is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America represents the dominating region, accounting for 43.7% of market revenue in 2025. Asia-Pacific is the fastest-growing region at a 9.14% CAGR, supported by an aging population and rising insurance coverage.

Key Findings of the Study

• The Peripheral Artery Disease Market reached a valuation of USD 5.90 billion in 2025.


• The market is projected to grow to USD 6.34 billion in 2026.


• The market includes data points reflecting operations up to 2026.


• The market is projected to reach USD 12.78 billion by 2035.


• The market is expected to grow at a CAGR of 8.10% during the forecast period from 2026 to 2035.


• Devices dominate the treatment type segment while Drugs represent the fastest-growing category.


• Hospitals hold the largest share by end user while Ambulatory Surgical Centers post the strongest growth.


• Intermittent claudication holds the largest share by disease stage while Critical limb ischemia is the fastest-growing area.


• Lower-extremity arteries dominate the anatomy treated segment while Renal-visceral arteries are the fastest-growing.


• North America holds the largest market share while Asia-Pacific is projected to grow at the fastest CAGR.


• Key players include Medtronic, Boston Scientific, Abbott Laboratories, Stryker, Philips Healthcare, and BD.